Breast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer MetastaticOvarian CancerCervical CarcinomaEndometrial Cancer
Investigational drug(s) / intervention(s)
Oncologic drugs administered for treatment of breast cancerOncologic drug administered for treatment of gynecologic cancer
Oncologic drugs administered for treatment of breast cancer: Data on oncologic drugs administered for treatment of breast cancer will be recorded
Oncologic drug administered for treatment of gynecologic cancer: Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Study summary
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
* Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
* Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.
Exclusion Criteria:
* no exclusion criteria
Primary outcome measure(s)
DFS — From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. To evaluate effect of drugs in terms of objective responses compared with registrational studies in medical therapy of breast and gynecological cancers: disease-free survival (DFS)
Trial sites (1)
Facility
City
Region
Status
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna
Italy
Recruiting
More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
